Co-deficiency of B7-H3 and B7-H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer

被引：0
作者：
Si S. [1 ]
Wang L. [1 ]
Cao H. [1 ]
Xu Y. [1 ]
Zhan Q. [1 ]
机构：
[1] Department of Gastroenterology, Wuxi People’s Hospital Affiliated to Nanjing Medical University, No. 299 Qing Yang Road, Wuxi
来源：
BMC Cancer | / 22卷 / 1期
基金：
中国国家自然科学基金;
关键词：
B7-H3; B7-H4; Immune cell infiltration; pancreatic cancer; prognosis;
D O I：
10.1186/s12885-022-09294-w
中图分类号：
学科分类号：
摘要：
Background: Immunotherapy is a novel hotspot for the treatment of pancreatic adenocarcinoma (PAAD). However, potential biomarkers which could identify the inflamed tumor microenvironment (TME) are urgently required. Methods: In the present study, we measured the levels of B7-H3, B7-H4, and major tumor-infiltrating immune cells (TIICs) using bioinformatics analyses and immunohistochemistry (IHC) staining on PAAD samples represented in the tissue microarray (TMA) format. Statistical analysis and figures exhibition were performed using R 4.1.0, SPSS 26.0, and GraphPad Prism 6.0. Results: B7-H3 and B7-H4 were up-regulated in PAAD compared with para-tumor tissues, and their expression exhibited no tight correlation in PAAD tissues. B7-H3 and B7-H4 were lowly expressed in well-differentiated PAAD tissues and correlated with poorly differentiated grades. Besides, single B7-H3 or B7-H4 expression exhibited limited prognostic value, but co-deficiency of B7-H3 and B7-H4 predicted a better prognosis in PAAD. Moreover, co-deficiency of B7-H3 and B7-H4 indicated immuno-hot tumors with high CD8 + T cell infiltration. Conclusions: Overall, combined B7-H3 and B7-H4 expression is a promising stratification strategy to assess prognosis and immunogenicity in PAAD, which could be used as a novel classifier in clinical practice. © 2022, The Author(s).
引用
收藏
相关论文
共 43 条
  • [1] Siegel R.L., Miller K.D., Fuchs H.E., Jemal A., Cancer Statistics, 2021, CA Cancer J Clin, 71, 1, pp. 7-33, (2021)
  • [2] Foley K., Kim V., Jaffee E., Zheng L., Current progress in immunotherapy for pancreatic cancer, Cancer Lett, 381, 1, pp. 244-251, (2016)
  • [3] Hilmi M., Bartholin L., Neuzillet C., Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?, World J Gastroenterol, 24, 20, pp. 2137-2151, (2018)
  • [4] Banerjee K., Kumar S., Ross K.A., Gautam S., Poelaert B., Nasser M.W., Aithal A., Bhatia R., Wannemuehler M.J., Narasimhan B., Et al., Emerging trends in the immunotherapy of pancreatic cancer, Cancer Lett, 417, pp. 35-46, (2018)
  • [5] Schizas D., Charalampakis N., Kole C., Economopoulou P., Koustas E., Gkotsis E., Ziogas D., Psyrri A., Karamouzis M.V., Immunotherapy for pancreatic cancer: A 2020 update, Cancer Treat Rev, 86, (2020)
  • [6] Tahkola K., Mecklin J.P., Wirta E.V., Ahtiainen M., Helminen O., Bohm J., Kellokumpu I., High immune cell score predicts improved survival in pancreatic cancer, Virchows Arch, 472, 4, pp. 653-665, (2018)
  • [7] Stenzel P.J., Schindeldecker M., Tagscherer K.E., Foersch S., Herpel E., Hohenfellner M., Hatiboglu G., Alt J., Thomas C., Haferkamp A., Et al., Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma, Transl Oncol, 13, 2, pp. 336-345, (2020)
  • [8] Leung J., Suh W.K., The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy, Immune Netw, 14, 6, pp. 265-276, (2014)
  • [9] Li Y.M., Yu J.M., Liu Z.Y., Yang H.J., Tang J., Chen Z.N., Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8(+) T Cells in Non-Small Cell Lung Cancer, Int J Mol Sci, 20, 20, (2019)
  • [10] Wei X.L., Liu Q.W., Liu F.R., Yuan S.S., Li X.F., Li J.N., Yang A.L., Ling Y.H., The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer, Oncoimmunology, 10, 1, (2021)
12345